JP2014528449A - 新規なイミダゾールキノリン系免疫系調節剤 - Google Patents

新規なイミダゾールキノリン系免疫系調節剤 Download PDF

Info

Publication number: JP2014528449A
Authority: JP; Japan
Prior art keywords: alkyl; heterocycle; cycloalkyl; optionally substituted; heteroatoms
Prior art date: 2011-10-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2014534658A

Other languages

English (en)

Japanese (ja)

Inventor

リップフォード，グレイソン，ビー．

ゼップ，チャールズ，エム．

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-04

Filing date

2012-10-03

Publication date

2014-10-27

2012-10-03 Application filed by Individual filed Critical Individual

2014-10-27 Publication of JP2014528449A publication Critical patent/JP2014528449A/ja

Status Pending legal-status Critical Current

Links

0 CCC[n]1c(c(cccc2)c2nc2*N(*)*)c2nc1* Chemical compound CCC[n]1c(c(cccc2)c2nc2*N(*)*)c2nc1* 0.000 description 11
GOWUDHPKGOIDIX-UHFFFAOYSA-N CN1CCN(CCN)CC1 Chemical compound CN1CCN(CCN)CC1 GOWUDHPKGOIDIX-UHFFFAOYSA-N 0.000 description 2
MCTWTZJPVLRJOU-UHFFFAOYSA-N C[n]1cncc1 Chemical compound C[n]1cncc1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
IJFOEELDPVHEGL-UHFFFAOYSA-N CC(C)N1CCSCC1 Chemical compound CC(C)N1CCSCC1 IJFOEELDPVHEGL-UHFFFAOYSA-N 0.000 description 1
XNRPMYWWKSCTSD-UHFFFAOYSA-N CCNc(c(N1CCN(C)CC1)nc1ccccc11)c1NCCN1CCOCC1 Chemical compound CCNc(c(N1CCN(C)CC1)nc1ccccc11)c1NCCN1CCOCC1 XNRPMYWWKSCTSD-UHFFFAOYSA-N 0.000 description 1
CECIZCZELUJLOQ-UHFFFAOYSA-N CN(C)CCNc1nc2ccccc2c(NCCc2c[nH]cn2)c1[N+]([O-])=O Chemical compound CN(C)CCNc1nc2ccccc2c(NCCc2c[nH]cn2)c1[N+]([O-])=O CECIZCZELUJLOQ-UHFFFAOYSA-N 0.000 description 1
AVFZOVWCLRSYKC-UHFFFAOYSA-N CN1CCCC1 Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
QPSYZQIITYUXDB-UHFFFAOYSA-N CN1CCN(CCNc2c(cccc3)c3nc(Cl)c2[N+]([O-])=O)CC1 Chemical compound CN1CCN(CCNc2c(cccc3)c3nc(Cl)c2[N+]([O-])=O)CC1 QPSYZQIITYUXDB-UHFFFAOYSA-N 0.000 description 1
CGHPLWUMJGRDEP-UHFFFAOYSA-N CN1CCN(CCNc2c3c(F)cc(F)cc3nc(Cl)c2[N+]([O-])=O)CC1 Chemical compound CN1CCN(CCNc2c3c(F)cc(F)cc3nc(Cl)c2[N+]([O-])=O)CC1 CGHPLWUMJGRDEP-UHFFFAOYSA-N 0.000 description 1
HVOYZOQVDYHUPF-UHFFFAOYSA-N CNCCN(C)C Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
CGMYZSGCTASEQF-UHFFFAOYSA-N Cc(cc1)ccc1C1=C=CCc(cccc2)c2C(C)=C1C Chemical compound Cc(cc1)ccc1C1=C=CCc(cccc2)c2C(C)=C1C CGMYZSGCTASEQF-UHFFFAOYSA-N 0.000 description 1
MGAYIUHYOBCPDM-UHFFFAOYSA-N [O-][N+](c(c(Cl)nc1c2c(F)cc(F)c1)c2Cl)=O Chemical compound [O-][N+](c(c(Cl)nc1c2c(F)cc(F)c1)c2Cl)=O MGAYIUHYOBCPDM-UHFFFAOYSA-N 0.000 description 1
RSFJVCHKGRUCIC-UHFFFAOYSA-N [O-][N+](c(c(Cl)nc1c2cccc1)c2Cl)=O Chemical compound [O-][N+](c(c(Cl)nc1c2cccc1)c2Cl)=O RSFJVCHKGRUCIC-UHFFFAOYSA-N 0.000 description 1
BLTZCROTWXIKLX-UHFFFAOYSA-N [O-][N+](c(c(Cl)nc1ccccc11)c1NCCc1c[nH]cn1)=O Chemical compound [O-][N+](c(c(Cl)nc1ccccc11)c1NCCc1c[nH]cn1)=O BLTZCROTWXIKLX-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Immunology (AREA)
Neurology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

JP2014534658A 2011-10-04 2012-10-03 新規なイミダゾールキノリン系免疫系調節剤 Pending JP2014528449A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161543082P	2011-10-04	2011-10-04
US61/543,082		2011-10-04
PCT/US2012/058566 WO2013052550A2 (en)	2011-10-04	2012-10-03	Novel imidazole quinoline-based immune system modulators

Publications (1)

Publication Number	Publication Date
JP2014528449A true JP2014528449A (ja)	2014-10-27

Family

ID=48044383

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2014534658A Pending JP2014528449A (ja)	2011-10-04	2012-10-03	新規なイミダゾールキノリン系免疫系調節剤

Country Status (8)

Country	Link
US (1)	US9873694B2 (2)
EP (1)	EP2763677B1 (2)
JP (1)	JP2014528449A (2)
AU (1)	AU2012318694B2 (2)
CA (1)	CA2850932A1 (2)
IL (1)	IL231957A0 (2)
IN (1)	IN2014KN00948A (2)
WO (1)	WO2013052550A2 (2)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9227969B2 (en)	2013-08-14	2016-01-05	Novartis Ag	Compounds and compositions as inhibitors of MEK
US10071079B2 (en)	2016-06-29	2018-09-11	Bristol-Myers Squibb Company	[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
BR112019001270A2 (pt)	2016-07-30	2019-04-30	Bristol-Myers Squibb Company	compostos indol substituídos com dimetoxifenila como inibidores de tlr7, tlr8 ou tlr9
JP7028861B2 (ja)	2016-09-09	2022-03-02	ブリストル－マイヤーズスクイブカンパニー	ピリジル置換のインドール化合物
WO2019028302A1 (en)	2017-08-04	2019-02-07	Bristol-Myers Squibb Company	SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS
KR102688509B1 (ko)	2017-08-04	2024-07-24	브리스톨-마이어스 스큅 컴퍼니	[1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
JP7265554B2 (ja)	2017-11-14	2023-04-26	ブリストル－マイヤーズスクイブカンパニー	置換インドール化合物
KR102781141B1 (ko)	2017-12-15	2025-03-13	브리스톨-마이어스 스큅 컴퍼니	치환된 인돌 에테르 화합물
EA202091484A1 (ru)	2017-12-18	2021-03-25	Бристол-Маерс Сквибб Компани	4-азаиндольные соединения
MX2020005462A (es)	2017-12-19	2020-09-07	Bristol Myers Squibb Co	Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).
JP7304352B2 (ja)	2017-12-19	2023-07-06	ブリストル－マイヤーズスクイブカンパニー	６－アザインドール化合物
WO2019126081A1 (en)	2017-12-19	2019-06-27	Bristol-Myers Squibb Company	Amide substituted indole compounds useful as tlr inhibitors
SG11202005733QA (en)	2017-12-20	2020-07-29	Bristol Myers Squibb Co	Diazaindole compounds
KR102730859B1 (ko)	2017-12-20	2024-11-15	브리스톨-마이어스 스큅 컴퍼니	아릴 및 헤테로아릴 치환된 인돌 화합물
EP3728218B1 (en)	2017-12-20	2021-12-01	Bristol-Myers Squibb Company	Amino indole compounds useful as tlr inhibitors
ES2963696T3 (es)	2018-10-24	2024-04-01	Bristol Myers Squibb Co	Compuestos diméricos de indol sustituidos
CN112955450A (zh)	2018-10-24	2021-06-11	百时美施贵宝公司	经取代的吲哚和吲唑化合物
US20220175762A1 (en) *	2019-03-15	2022-06-09	Birdie Biopharmaceuticals, Inc.	Immune modulatory compositions and methods for treating cancers
KR102904576B1 (ko)	2019-05-09	2025-12-24	브리스톨-마이어스 스큅 컴퍼니	치환된 벤즈이미다졸론 화합물
EP4041730A1 (en)	2019-10-01	2022-08-17	Bristol-Myers Squibb Company	Substituted bicyclic heteroaryl compounds
CN114829350B (zh)	2019-10-04	2024-05-28	百时美施贵宝公司	经取代的咔唑化合物
WO2021150613A1 (en)	2020-01-20	2021-07-29	Incyte Corporation	Spiro compounds as inhibitors of kras
US11739102B2 (en)	2020-05-13	2023-08-29	Incyte Corporation	Fused pyrimidine compounds as KRAS inhibitors
US11999752B2 (en)	2020-08-28	2024-06-04	Incyte Corporation	Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en)	2020-10-02	2022-04-07	Incyte Corporation	Bicyclic dione compounds as inhibitors of kras
WO2022204112A1 (en)	2021-03-22	2022-09-29	Incyte Corporation	Imidazole and triazole kras inhibitors
CR20230478A (es)	2021-04-16	2023-11-30	Gilead Sciences Inc	Compuestos de tienopirrol.
MX2024000357A (es)	2021-07-07	2024-02-12	Incyte Corp	Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
US12600717B2 (en)	2021-07-14	2026-04-14	Incyte Corporation	Tricyclic compounds as inhibitors of KRAS
US12441742B2 (en)	2021-08-31	2025-10-14	Incyte Corporation	Naphthyridine compounds as inhibitors of KRAS
KR20240056747A (ko)	2021-09-10	2024-04-30	길리애드 사이언시즈, 인코포레이티드	티에노피롤 화합물
WO2023049697A1 (en)	2021-09-21	2023-03-30	Incyte Corporation	Hetero-tricyclic compounds as inhibitors of kras
CA3234375A1 (en)	2021-10-01	2023-04-06	Incyte Corporation	Pyrazoloquinoline kras inhibitors
WO2023064857A1 (en)	2021-10-14	2023-04-20	Incyte Corporation	Quinoline compounds as inhibitors of kras

Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60123488A (ja) *	1983-11-18	1985-07-02	ライカー　ラボラトリース　インコーポレーテツド	１ｈ‐イミダゾ〔４，５‐ｃ〕キノリン類および１ｈ‐イミダゾ〔４，５‐ｃ〕キノリン‐４‐アミン類
WO2000009506A1 (en) *	1998-08-12	2000-02-24	Hokuriku Seiyaku Co., Ltd.	1h-imidazopyridine derivatives
JP2007524615A (ja) *	2003-06-20	2007-08-30	コーリーファーマシューティカルゲーエムベーハー	低分子トール様レセプター（ｔｌｒ）アンタゴニスト
WO2007109810A2 (en) *	2006-03-23	2007-09-27	Novartis Ag	Methods for the preparation of imidazole-containing compounds
JP2008531567A (ja) *	2005-02-23	2008-08-14	コーリーファーマシューティカルグループ，インコーポレイテッド	ヒドロキシアルキル置換イミダゾキノリン化合物および方法
EP1972629A1 (en) *	2007-03-23	2008-09-24	Mutabilis SA	New imidazolo-heteroaryl derivatives with antibacterial properties
WO2010030785A2 (en) *	2008-09-10	2010-03-18	Kalypsys Inc.	Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20100160314A1 (en) *	2006-09-05	2010-06-24	Lipford Grayson B	Small Molecule Inhibitors of Toll-Like Receptor 9
WO2011068233A1 (en) *	2009-12-03	2011-06-09	Dainippon Sumitomo Pharma Co., Ltd.	Imidazoquinolines which act via toll - like receptors (tlr)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3854480A (en)	1969-04-01	1974-12-17	Alza Corp	Drug-delivery system
US4452775A (en)	1982-12-03	1984-06-05	Syntex (U.S.A.) Inc.	Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en)	1986-10-24	1991-12-24	Southern Research Institute	Method of potentiating an immune response
US5133974A (en)	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5407686A (en)	1991-11-27	1995-04-18	Sidmak Laboratories, Inc.	Sustained release composition for oral administration of active ingredient
US5491084A (en)	1993-09-10	1996-02-13	The Trustees Of Columbia University In The City Of New York	Uses of green-fluorescent protein
ATE509102T1 (de)	1994-07-15	2011-05-15	Univ Iowa Res Found	Immunomodulatorische oligonukleotide
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5736152A (en)	1995-10-27	1998-04-07	Atrix Laboratories, Inc.	Non-polymeric sustained release delivery system
AR006928A1 (es)	1996-05-01	1999-09-29	Pioneer Hi Bred Int	Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
WO1998037919A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en)	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE458053T1 (de)	1997-05-07	2010-03-15	Schering Corp	Menschliche toll-like-rezeptorproteine, zugehörige reagenzien und verfahren
AU7690898A (en)	1997-05-20	1998-12-11	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
ATE356630T1 (de)	1998-04-03	2007-04-15	Univ Iowa Res Found	Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1077708A1 (en)	1998-05-06	2001-02-28	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
PL350050A1 (en)	1999-01-22	2002-10-21	Elan Pharm Inc	Acyl derivatives which treat vla-4 related disorders
EP1220684B2 (en)	1999-09-27	2010-07-14	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
NZ522327A (en)	2000-05-25	2004-09-24	Schering Corp	Mammalian DNAX Toll-like receptor protein, DTLR 10, antibodies and medicaments made therefrom and use in treating immunological disorders
IL160157A0 (en)	2001-08-17	2004-07-25	Coley Pharm Group Inc	Combination motif immune stimulation oligonucleotides with improved activity
WO2005016235A2 (en)	2003-04-14	2005-02-24	The Regents Of The University Of California	Combined use of impdh inhibitors with toll-like receptor agonists
KR20080083270A (ko) *	2005-11-04	2008-09-17	콜레이 파마시티컬 그룹, 인코포레이티드	하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
US20080149123A1 (en) *	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
US7943771B2 (en) *	2007-01-24	2011-05-17	Chemagis Ltd.	Imiquimod production process
ES2607901T3 (es) *	2007-01-31	2017-04-04	Chongxi Yu	Profármacos hidrosolubles cargados positivamente de 1H-imidazo[4,5-c]quinolin-4-aminas y compuestos relacionados con ratas de penetración de piel muy altas
US8728486B2 (en) *	2011-05-18	2014-05-20	University Of Kansas	Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds

2012
- 2012-10-03 WO PCT/US2012/058566 patent/WO2013052550A2/en not_active Ceased
- 2012-10-03 US US14/349,254 patent/US9873694B2/en not_active Expired - Fee Related
- 2012-10-03 CA CA2850932A patent/CA2850932A1/en not_active Abandoned
- 2012-10-03 EP EP12837804.9A patent/EP2763677B1/en active Active
- 2012-10-03 AU AU2012318694A patent/AU2012318694B2/en not_active Ceased
- 2012-10-03 JP JP2014534658A patent/JP2014528449A/ja active Pending
- 2012-10-03 IN IN948KON2014 patent/IN2014KN00948A/en unknown
2014
- 2014-04-06 IL IL231957A patent/IL231957A0/en unknown

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60123488A (ja) *	1983-11-18	1985-07-02	ライカー　ラボラトリース　インコーポレーテツド	１ｈ‐イミダゾ〔４，５‐ｃ〕キノリン類および１ｈ‐イミダゾ〔４，５‐ｃ〕キノリン‐４‐アミン類
WO2000009506A1 (en) *	1998-08-12	2000-02-24	Hokuriku Seiyaku Co., Ltd.	1h-imidazopyridine derivatives
JP2007524615A (ja) *	2003-06-20	2007-08-30	コーリーファーマシューティカルゲーエムベーハー	低分子トール様レセプター（ｔｌｒ）アンタゴニスト
JP2008531567A (ja) *	2005-02-23	2008-08-14	コーリーファーマシューティカルグループ，インコーポレイテッド	ヒドロキシアルキル置換イミダゾキノリン化合物および方法
WO2007109810A2 (en) *	2006-03-23	2007-09-27	Novartis Ag	Methods for the preparation of imidazole-containing compounds
US20100160314A1 (en) *	2006-09-05	2010-06-24	Lipford Grayson B	Small Molecule Inhibitors of Toll-Like Receptor 9
EP1972629A1 (en) *	2007-03-23	2008-09-24	Mutabilis SA	New imidazolo-heteroaryl derivatives with antibacterial properties
WO2010030785A2 (en) *	2008-09-10	2010-03-18	Kalypsys Inc.	Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011068233A1 (en) *	2009-12-03	2011-06-09	Dainippon Sumitomo Pharma Co., Ltd.	Imidazoquinolines which act via toll - like receptors (tlr)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6016021933; Ｊｉｎｇｘｉ　ＨｕａｇｏｎｇＶｏｌ．２４（３）, 2007, ｐ．３０４-３０７ *

Also Published As

Publication number	Publication date
AU2012318694A1 (en)	2014-05-22
WO2013052550A2 (en)	2013-04-11
IL231957A0 (en)	2014-05-28
WO2013052550A3 (en)	2014-05-15
IN2014KN00948A (2)	2015-08-21
EP2763677A4 (en)	2015-05-20
EP2763677B1 (en)	2020-02-26
US20140242121A1 (en)	2014-08-28
US9873694B2 (en)	2018-01-23
AU2012318694B2 (en)	2016-12-22
CA2850932A1 (en)	2013-04-11
EP2763677A2 (en)	2014-08-13

Legal Events

Date	Code	Title	Description
2015-10-01	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151001
2016-05-02	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160428
2016-06-14	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160614
2016-09-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160913
2016-12-20	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161220

Publication	Publication Date	Title
JP6093759B2 (ja)	2017-03-08	新規の免疫系調節剤
JP2014528449A (ja)	2014-10-27	新規なイミダゾールキノリン系免疫系調節剤
EP2713737B1 (en)	2016-04-20	Novel immune system modulators
JP2017525711A (ja)	2017-09-07	新規なｎ２，ｎ４，ｎ７，６−四置換プテリジン−２，４，７−トリアミンおよび２，４，６，７−四置換プテリジン化合物ならびにその合成方法および使用
JP2007524615A (ja)	2007-08-30	低分子トール様レセプター（ｔｌｒ）アンタゴニスト
CN1809357B (zh)	2010-12-22	小分子Toll样受体(TLR)拮抗剂
JP2023512229A (ja)	2023-03-24	トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
HK1196505A (en)	2014-12-19	Novel immune system modulators